3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
5
Sarcoma, Endometrial Stromal
1
Perivascular Epithelioid Cell Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Breast Diseases
1
Brain Neoplasms
1
Brain Diseases
1
Advanced Breast Cancer
1
Adenosarcoma of the uterus
1
Interventions
Letrozole
5
Fulvestrant
5
trastuzumab deruxtecan
2
toripalimab
2
sacituzumab govitecan
2
palbociclib
2
elacestrant
2
abemaciclib
2
Injections
2
Anastrozole
2
AZD9833
2
ribociclib
1
pyrotinib
1
exemestane
1
eribulin
1
disitamab vedotin
1
dalpiciclib
1
Vinorelbine
1
Selective Estrogen Receptor Modulators
1
Ritonavir
1
RAD1901
1
Paclitaxel
1
Lead
1
Itraconazole
1
Goserelin
1
Gonadotropin-Releasing Hormone
1
Everolimus
1
Docetaxel
1
Bevacizumab
1
Aromatase Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Breast Cancer
×
RAD1901
×
1 year
×
Clear all
NCT06382948
2026-04-03
ADELA
MedSIR
Phase 3
Recruiting
240 enrolled